Traws Pharma shareholders approve 2M share increase in incentive plan and warrant issuance at annual meeting

Traws Pharma, Inc.

Stockholders approved amendment to 2021 Incentive Compensation Plan, increasing authorized shares by 2,000,000 (4,821,796 for, 1,694,075 against).
Proposal 4 approved issuance of shares upon exercise of Series B and C Warrants issued under April 15, 2026 Securities Purchase Agreement (2,270,414 for, 151,196 against).
All seven director nominees elected; KPMG ratified as auditor for FY 2026 (7,659,805 for).
Certain shares (3,486,423) excluded from voting on Proposal 4 per Nasdaq rules; total outstanding shares 15,150,669 as of May 18, 2026 record date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.